KDIGO 2024 狼疮性肾炎管理临床实践指南执行摘要
KDIGO 在2021年肾小球疾病指南基础上,因两种新药获批用于狼疮性肾炎管理,发布了首个指南更新。本文提供狼疮性肾炎章节最重要变更的执行摘要,作为快速参考。
要点
- 2021年KDIGO肾小球疾病指南后,狼疮性肾炎治疗领域有两种新药获批。
- KDIGO据此启动指南定期更新机制,本文为狼疮性肾炎章节更新摘要。
- 执行摘要旨在为临床医生提供指南关键变更的快速参考。
核心结论
- KDIGO基于新药获批对2021年肾小球疾病指南中狼疮性肾炎章节进行了更新,并发布执行摘要供快速参考。
研究设计与样本
- KDIGO临床实践指南更新,针对2021年肾小球疾病指南中狼疮性肾炎章节,基于新药获批等新进展进行修订。
主要发现
- 2021年指南发布后,两种新药获监管批准用于狼疮性肾炎管理,促成首次KDIGO指南更新。
临床怎么用
- 临床医生可借助该执行摘要快速了解狼疮性肾炎管理指南的重要变更。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases was published in 2021. Since then, the pace of drug development for glomerular diseases has accelerated, due in large part to rapidly accumulating insights into disease pathogenesis from genetic and molecular studies of afflicted patients. To keep the Glomerular Diseases Guideline as current as possible, KDIGO made a commitment to the nephrology community to provide periodic updates, based on new developments for each disease. After the 2021 guideline was published, two novel drugs received regulatory approval for the management of lupus nephritis, leading to the first KDIGO guideline update. Herein, an executive summary of the most important guideline changes from the Lupus Nephritis chapter is provided as a quick reference.
引用
- Rovin BH, Ayoub IM, Chan TM, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024. PMID: 38182299. doi:10.1016/j.kint.2023.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。